Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Multidisciplinary Sciences
Bryan A. Johnson et al.
Summary: The genetic mutation in SARS-CoV-2 resulted in better fitness in some cells but lower replication capacity in human respiratory cell lines. Despite reducing disease symptoms, the Delta PRRA mutant provided protection against rechallenge with the wildtype SARS-CoV-2.
Article
Biochemistry & Molecular Biology
Piyada Supasa et al.
Summary: Research on the UK-dominant variant B.1.1.7 shows that it is harder to neutralize than the parental virus, but widespread escape from antibodies or monoclonal antibodies has not been observed yet.
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article
Microbiology
Allison J. Greaney et al.
Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Gabriele Cerutti et al.
Summary: Structural analysis revealed that seven potent NTD-directed neutralizing antibodies target a common surface on NTD, forming a single supersite different from the recognition pattern of RBD-directed antibodies.
CELL HOST & MICROBE
(2021)
Letter
Medicine, General & Internal
Keiya Uriu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Houriiyah Tegally et al.
Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Multidisciplinary Sciences
Steven A. Kemp et al.
Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.
Article
Biochemistry & Molecular Biology
Constantinos Kurt Wibmer et al.
Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.
Article
Multidisciplinary Sciences
Sebastian Weigang et al.
Summary: In a longitudinal case study, researchers demonstrate that SARS-CoV-2 variants with reduced sensitivity to neutralizing antibodies can evolve within persistently infected immunosuppressed patients. The study suggests that immunocompromised patients may serve as a potential source for the emergence of harmful variants, although immune control against these variants can still be achieved in some cases through the generation of neutralizing antibodies upon lowering immunosuppressive treatment.
NATURE COMMUNICATIONS
(2021)
Article
Biology
Farina Karim et al.
Summary: Conflicting reports exist on the effects of HIV on COVID-19. In this study, it was found that participants living with HIV had more severe outcomes during the second wave of infection, with lower CD4 T cell counts and higher neutrophil to lymphocyte ratios associated with disease severity. Conversely, in the first wave, HIV seemed to modulate SARS-CoV-2 immune responses to a similar degree in both HIV negative and positive individuals.
Article
Biochemistry & Molecular Biology
Naveenchandra Suryadevara et al.
Summary: The study found that a subset of human monoclonal antibodies derived from convalescent SARS-CoV-2 patients possess neutralizing activity, with two antibodies capable of inhibiting infection. Mechanistic studies revealed these antibodies neutralize in part by inhibiting post-attachment steps in the infection cycle.
Article
Biochemistry & Molecular Biology
Matthew McCallum et al.
Summary: The study identifies 41 human monoclonal antibodies that recognize the N-terminal domain of the SARS-CoV-2 spike protein and exhibit strong neutralizing activity. These antibodies inhibit cell-to-cell fusion, activate effector functions, and protect animals from virus challenge, highlighting the importance of NTD-specific neutralizing antibodies for protective immunity and vaccine development. Several SARS-CoV-2 variants with mutations in the NTD supersite suggest ongoing selective pressure on the virus.
Article
Biochemistry & Molecular Biology
Sarah A. Clark et al.
Summary: The study reveals that mutations occurring during the evolution of SARS-CoV-2 virus may lead to resistance against antibodies, posing challenges to long-term efficacy.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.
Article
Biochemistry & Molecular Biology
Delphine Planas et al.
Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Chang Liu et al.
Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.
Article
Immunology
Kristen A. Earle et al.
Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.
Article
Multidisciplinary Sciences
Allison J. Greaney et al.
Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.
NATURE COMMUNICATIONS
(2021)
Article
Microbiology
Liang Chen et al.
Summary: The study documented the microevolution of SARS-CoV-2 in an immunosuppressed patient undergoing steroid and convalescent plasma therapy, showing multiple NTD and RBD mutations. This suggests that immunocompromised patients may serve as breeding grounds for immune escape mutants, highlighting the need for enhanced measures to reduce transmission.
Letter
Immunology
Seth A. Hoffman et al.
Summary: The study reveals that patients with HIV/AIDS may carry variants of SARS-CoV-2 that are resistant to neutralization, highlighting the importance of monitoring infections in immunocompromised individuals.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Petra Mlcochova et al.
Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.
Article
Multidisciplinary Sciences
Xiangyang Chi et al.
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
Letter
Medicine, General & Internal
Bina Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Biochemical Research Methods
Michael Vilsker et al.
Article
Medicine, General & Internal
G. Meintjes et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2018)
Article
Immunology
Vivian Iida Avelino-Silva et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
(2016)
Article
Immunology
Maria G. Guzman et al.
EMERGING INFECTIOUS DISEASES
(2007)
Article
Multidisciplinary Sciences
DJ Smith et al.
Article
Medicine, General & Internal
EL Murphy et al.
ANNALS OF INTERNAL MEDICINE
(2001)
Article
Multidisciplinary Sciences
B Korber et al.
